196 related articles for article (PubMed ID: 36365185)
21. Predicting Human Fetal Drug Exposure Through Maternal-Fetal PBPK Modeling and In Vitro or Ex Vivo Studies.
Balhara A; Kumar AR; Unadkat JD
J Clin Pharmacol; 2022 Sep; 62 Suppl 1(Suppl 1):S94-S114. PubMed ID: 36106781
[TBL] [Abstract][Full Text] [Related]
22. Development of a physiologically based toxicokinetic model for lead in pregnant women: The role of bone tissue in the maternal and fetal internal exposure.
Ali Daoud Y; Tebby C; Beaudouin R; Brochot C
Toxicol Appl Pharmacol; 2023 Oct; 476():116651. PubMed ID: 37549741
[TBL] [Abstract][Full Text] [Related]
23. Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy.
Abduljalil K; Pansari A; Jamei M
J Pharmacokinet Pharmacodyn; 2020 Aug; 47(4):361-383. PubMed ID: 32840724
[TBL] [Abstract][Full Text] [Related]
24. Predicting fetal exposure of crizotinib during pregnancy: Combining human ex vivo placenta perfusion data with physiologically-based pharmacokinetic modeling.
Roelofsen D; van Hove H; Bukkems V; Russel F; Eliesen G; Greupink R
Toxicol In Vitro; 2022 Dec; 85():105471. PubMed ID: 36096459
[TBL] [Abstract][Full Text] [Related]
25. Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model.
Peng J; Ladumor MK; Unadkat JD
Drug Metab Dispos; 2022 May; 50(5):613-623. PubMed ID: 35149540
[TBL] [Abstract][Full Text] [Related]
26. Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the model for passive placental permeability drugs.
Zhang Z; Unadkat JD
Drug Metab Dispos; 2017 Aug; 45(8):939-946. PubMed ID: 28049636
[TBL] [Abstract][Full Text] [Related]
27. Physiologically Based Pharmacokinetic Modeling in Pregnant Women Suggests Minor Decrease in Maternal Exposure to Olanzapine.
Zheng L; Yang H; Dallmann A; Jiang X; Wang L; Hu W
Front Pharmacol; 2021; 12():793346. PubMed ID: 35126130
[TBL] [Abstract][Full Text] [Related]
28. Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations.
Ke AB; Greupink R; Abduljalil K
CPT Pharmacometrics Syst Pharmacol; 2018 Feb; 7(2):103-110. PubMed ID: 29349870
[TBL] [Abstract][Full Text] [Related]
29. Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and Raltegravir.
Liu XI; Momper JD; Rakhmanina NY; Green DJ; Burckart GJ; Cressey TR; Mirochnick M; Best BM; van den Anker JN; Dallmann A
Clin Pharmacokinet; 2021 Jun; 60(6):795-809. PubMed ID: 33527213
[TBL] [Abstract][Full Text] [Related]
30. Estimation of placental and lactational transfer and tissue distribution of atrazine and its main metabolites in rodent dams, fetuses, and neonates with physiologically based pharmacokinetic modeling.
Lin Z; Fisher JW; Wang R; Ross MK; Filipov NM
Toxicol Appl Pharmacol; 2013 Nov; 273(1):140-58. PubMed ID: 23958493
[TBL] [Abstract][Full Text] [Related]
31. Preliminary physiologically based pharmacokinetic modeling of renally cleared drugs in Chinese pregnant women.
Song L; Yu Z; Xu Y; Li X; Liu X; Liu D; Zhou T
Biopharm Drug Dispos; 2020 Jun; 41(6):248-267. PubMed ID: 32520400
[TBL] [Abstract][Full Text] [Related]
32. Estimating fetal exposure to the P-gp substrates, corticosteroids, by PBPK modeling to inform prevention of neonatal respiratory distress syndrome.
Anoshchenko O; Milad MA; Unadkat JD
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1057-1070. PubMed ID: 34273255
[TBL] [Abstract][Full Text] [Related]
33. Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models.
De Sousa Mendes M; Hirt D; Vinot C; Valade E; Lui G; Pressiat C; Bouazza N; Foissac F; Blanche S; Lê MP; Peytavin G; Treluyer JM; Urien S; Benaboud S
Br J Clin Pharmacol; 2016 Apr; 81(4):646-57. PubMed ID: 26518984
[TBL] [Abstract][Full Text] [Related]
34. Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Caffeine Disposition in Pregnancy.
Darakjian LI; Kaddoumi A
Mol Pharm; 2019 Mar; 16(3):1340-1349. PubMed ID: 30689395
[TBL] [Abstract][Full Text] [Related]
35. Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments.
Bukkems VE; van Hove H; Roelofsen D; Freriksen JJM; van Ewijk-Beneken Kolmer EWJ; Burger DM; van Drongelen J; Svensson EM; Greupink R; Colbers A
Clin Pharmacokinet; 2022 Aug; 61(8):1129-1141. PubMed ID: 35579825
[TBL] [Abstract][Full Text] [Related]
36. Dose Adjustment of Quetiapine and Aripiprazole for Pregnant Women Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Zheng L; Tang S; Tang R; Xu M; Jiang X; Wang L
Clin Pharmacokinet; 2021 May; 60(5):623-635. PubMed ID: 33251573
[TBL] [Abstract][Full Text] [Related]
37. Development of a Generic Fetal Physiologically Based Pharmacokinetic Model and Prediction of Human Maternal and Fetal Organ Concentrations of Cefuroxime.
Liu XI; Green DJ; van den Anker J; Ahmadzia HK; Burckart GJ; Dallmann A
Clin Pharmacokinet; 2024 Jan; 63(1):69-78. PubMed ID: 37962827
[TBL] [Abstract][Full Text] [Related]
38. Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling.
Schalkwijk S; Buaben AO; Freriksen JJM; Colbers AP; Burger DM; Greupink R; Russel FGM
Clin Pharmacokinet; 2018 Jun; 57(6):705-716. PubMed ID: 28744795
[TBL] [Abstract][Full Text] [Related]
39. Model-Informed Dose Optimization in Pregnancy.
Chaphekar N; Caritis S; Venkataramanan R
J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S63-S76. PubMed ID: 33205432
[TBL] [Abstract][Full Text] [Related]
40. Quantification of sertraline maternal/fetal ratio and amniotic fluid concentration using a pregnancy physiologically based pharmacokinetic model.
Lartey D; Jateng D; Li M; Nguyen C; Crentsil V; Beitz J; George B
Br J Clin Pharmacol; 2023 Jun; ():. PubMed ID: 37312614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
